Development of novel radioimmunotherapy strategies to overcome the interstitial barrier to improve the prognosis of refractory solid tumors
| Project/Area Number |
18H02774
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 52040:Radiological sciences-related
|
|---|
| Research Institution | National Institutes for Quantum Science and Technology |
|---|
Principal Investigator |
Tsuji Atsushi 国立研究開発法人量子科学技術研究開発機構, 量子医科学研究所 分子イメージング診断治療研究部, グループリーダー (60303559)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
眞鍋 史乃 星薬科大学, 薬学部, 教授 (60300901)
安永 正浩 国立研究開発法人国立がん研究センター, 先端医療開発センター, 分野長 (80450576)
|
|---|
| Project Period (FY) |
2018-04-01 – 2023-03-31
|
| Project Status |
Completed (Fiscal Year 2022)
|
| Budget Amount *help |
¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2022: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2021: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2020: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2019: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2018: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
|
|---|
| Keywords | 核医学 / 核医学治療 / RI治療 |
|---|
| Outline of Final Research Achievements |
The purpose of this study was to overcome the interstitial barrier that prevents drug delivery and to establish a new radioimmunotherapy strategy that is effective against intractable solid tumors. Cancer stroma-targeting antibodies were highly accumulated in a solid tumor model with abundant cancer stroma. The antibody labeled with beta-emitting nuclide Y-90 showed a promising treatment for pancreatic cancer alone. Furthermore, when a release-type ADC was used in combination, an even higher therapeutic effect was obtained. A characteristic pathological image was observed in the combination group. It is considered that the cell cycle was arrested in the mitotic phase due to the influence of the anticancer drug used for ADC. It is assumed that this effect was responsible for the radiation sensitization effect. Our therapeutic strategy has shown promise for the treatment of refractory solid tumors.
|
| Academic Significance and Societal Importance of the Research Achievements |
間質でリリースされるADCを利用することで、ベータ線放出Y-90標識抗体の治療効果を高めることを示すことができた。我々の治療戦略は、難治性固形癌の治療に有望であることが示された。今後、臨床応用が期待される。
|
Report
(6 results)
Research Products
(13 results)
-
-
-
[Journal Article] In Vitro Evaluation of No-carrier-added Radiolabeled Cisplatin ([189, 191Pt]cisplatin) Emitting Auger Electrons2021
Author(s)
Obata, H., Tsuji, A.B., Sudo, H., Sugyo, A., Minegishi, K., Nagatsu, K., Ogawa, M., Zhang, M.R.
-
Journal Title
Int. J. Mol. Sci.
Volume: 22
Issue: 9
Pages: 4622-4622
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-
-
